Your browser doesn't support javascript.
loading
A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in Thailand.
Jiamsiri, Suchada; Rhee, Chulwoo; Ahn, Hyeon Seon; Poudyal, Nimesh; Seo, Hyeong-Won; Klinsupa, Worrawan; Nilyanimit, Pornjarim; Premsri, Nakorn; Namwat, Chawetsan; Vonpunsawad, Sompong; Chon, Yun; Park, Sunju; Kim, Deok-Ryun; Unger, Elizabeth R; Markowitz, Lauri; Poovorawan, Yong; Rerks-Ngarm, Supachai; Excler, Jean Louis; Lynch, Julia.
Afiliação
  • Jiamsiri S; Division of Vaccine Preventable Diseases, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
  • Rhee C; International Vaccine Institute, Seoul, Republic of Korea.
  • Ahn HS; International Vaccine Institute, Seoul, Republic of Korea.
  • Poudyal N; International Vaccine Institute, Seoul, Republic of Korea.
  • Seo HW; International Vaccine Institute, Seoul, Republic of Korea.
  • Klinsupa W; Division of Vaccine Preventable Diseases, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
  • Nilyanimit P; Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Premsri N; National Vaccine Institute, Ministry of Public Health, Nonthaburi, Thailand.
  • Namwat C; Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
  • Vonpunsawad S; Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Chon Y; International Vaccine Institute, Seoul, Republic of Korea.
  • Park S; International Vaccine Institute, Seoul, Republic of Korea.
  • Kim DR; International Vaccine Institute, Seoul, Republic of Korea.
  • Unger ER; Chronic Viral Diseases Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
  • Markowitz L; Viral Vaccine Preventable Diseases Branch, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
  • Poovorawan Y; Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Rerks-Ngarm S; Division of Vaccine Preventable Diseases, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
  • Excler JL; International Vaccine Institute, Seoul, Republic of Korea.
  • Lynch J; International Vaccine Institute, Seoul, Republic of Korea.
PLoS One ; 17(4): e0267294, 2022.
Article em En | MEDLINE | ID: mdl-35482803
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Papillomavirus / Alphapapillomavirus / Vacinas contra Papillomavirus Tipo de estudo: Clinical_trials / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Limite: Female / Humans / Male País como assunto: Asia Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por Papillomavirus / Alphapapillomavirus / Vacinas contra Papillomavirus Tipo de estudo: Clinical_trials / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Limite: Female / Humans / Male País como assunto: Asia Idioma: En Ano de publicação: 2022 Tipo de documento: Article